About Medium-wave-sensitive opsin 2
Medium-wave-sensitive opsin 2 (OPN1MW2) is a protein
from Homo sapiens identified by UniProt accession
P0DN77, 364 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Medium-wave-sensitive opsin 2 |
|---|
| UniProt accession | P0DN77 |
|---|
| Gene | OPN1MW2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 364 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (36)
Diseases linked to this target (Open Targets).
- red-green color blindness · score 0.15
- red color blindness · score 0.10
- Tritanopia · score 0.08
- Myopia · score 0.07
- bradyopsia · score 0.07
- age-related macular degeneration · score 0.07
- hyperopia, high · score 0.07
- gelatinous drop-like corneal dystrophy · score 0.06
- X-linked retinal dysplasia · score 0.06
- Familial exudative vitreoretinopathy · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0DN77-F1 | alphafold | PREDICTED | 82.66 | — |
Amino-acid sequence (364 residues)
MAQQWSLQRL AGRHPQDSYE DSTQSSIFTY TNSNSTRGPF EGPNYHIAPR WVYHLTSVWM IFVVIASVFT NGLVLAATMK FKKLRHPLNW ILVNLAVADL AETVIASTIS VVNQVYGYFV LGHPMCVLEG YTVSLCGITG LWSLAIISWE RWMVVCKPFG NVRFDAKLAI VGIAFSWIWA AVWTAPPIFG WSRYWPHGLK TSCGPDVFSG SSYPGVQSYM IVLMVTCCIT PLSIIVLCYL QVWLAIRAVA KQQKESESTQ KAEKEVTRMV VVMVLAFCFC WGPYAFFACF AAANPGYPFH PLMAALPAFF AKSATIYNPV IYVFMNRQFR NCILQLFGKK VDDGSELSSA SKTEVSSVSS VSPA
Explore Medium-wave-sensitive opsin 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets